Blood Disease Clinical Trial
— RCTOfficial title:
The Effect of Virtual Reality on Pain and Musculoskeletal Dysfunction in Children With Sickle Cell Disease: A Randomized Controlled Trial
Primary aim to determine the effects of immersive VR on pain management in children with SCD. Secondary aim to determine the effects of immersive VR in musculoskeletal dysfunction in children with SCD and health-related quality of life.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | October 20, 2023 |
Est. primary completion date | September 9, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 18 Years |
Eligibility | Inclusion Criteria: - The inclusion criteria are as following: patients aged between 6-18 years of both genders diagnosed with SCD, with hip avascular necrosis (AVN), with joints pain, children with SCD post hip surgery, with motor impairment and gait difficulty, with restricted ROM in lower limb, children with recent crisis of SCD. Exclusion Criteria: - The exclusion criteria are the children with previous stroke or other neurologic disorders and cardiopulmonary disorders that limits the functional activities of the participants will be excluded. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Afnan Bkri |
Agrawal AK, Robertson S, Litwin L, Tringale E, Treadwell M, Hoppe C, Marsh A. Virtual reality as complementary pain therapy in hospitalized patients with sickle cell disease. Pediatr Blood Cancer. 2019 Feb;66(2):e27525. doi: 10.1002/pbc.27525. Epub 2018 Oct 26. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Wong-Baker Pain Faces Scale | pain | 6. weeks | |
Secondary | The PedsQL™ | The PedsQL™ measurement model was designed as a modular approach to measuring pediatric health-related quality of life and developed to integrate the relative merits of generic and disease-specific approaches. The PedsQL™ has demonstrated reliability, validity, sensitivity, and responsiveness for child | 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00106015 -
Diamond Blackfan Anemia Registry (DBAR)
|
||
Completed |
NCT00059293 -
Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
|
||
Completed |
NCT00023530 -
Blood and Marrow Transplant Clinical Research Network
|
N/A | |
Not yet recruiting |
NCT05983536 -
The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
|
||
Recruiting |
NCT03548766 -
Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping
|
Phase 3 | |
Completed |
NCT00007371 -
Hepatitis C in Clinically Discordant Hemophilic Siblings
|
N/A | |
Completed |
NCT00000587 -
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
|
Phase 2 | |
Completed |
NCT00005682 -
Aplastic Anemia Epidemiology: Incidence and Case-control
|
N/A | |
Completed |
NCT00005305 -
Hepatitis Delta Infections in Hemophiliacs
|
N/A | |
Completed |
NCT00005304 -
Delta Hepatitis and Liver Disease in Hemophiliacs
|
||
Completed |
NCT00005277 -
Cooperative Study of The Clinical Course of Sickle Cell Disease
|
N/A | |
Completed |
NCT00035763 -
Pain in Sickle Cell Epidemiologic Study
|
N/A | |
Completed |
NCT00005300 -
Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease
|
N/A | |
Recruiting |
NCT04600609 -
Examining the Experiences of Children With Blood Disorders
|
||
Not yet recruiting |
NCT03881917 -
Cystatin c and Beta 2 Microglobulin in Thalassemic Children.
|
||
Completed |
NCT00005556 -
Retention of Bone Marrow Donors in a National Registry
|
N/A | |
Completed |
NCT00000597 -
Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders
|
Phase 3 | |
Completed |
NCT03586180 -
Medical Clowning: Needs Assessment and Implication for Hospitalized Children With Cancer/Blood Disease
|
||
Recruiting |
NCT03848962 -
Collection and Distribution of Biospecimens for Novel Research Uses
|
||
Terminated |
NCT00486720 -
Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
|
Phase 2 |